Immunic shareholders approve 6M share increase to equity plan, elect directors, ratify auditor

IMMUNIC, INC.

Amendment to 2019 Omnibus Equity Plan approved, increasing authorized shares by 6,000,000 to total 8,644,887.
Michael Bonney, Thorvald Nagel, and Richard Rudick elected as Class III directors to serve until 2029.
Baker Tilly US, LLP ratified as independent registered public accounting firm for fiscal year 2026.
Plan amendment vote: 4,391,782 for, 1,361,843 against, 24,538 abstain, and 3,107,100 broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.